

New York District

Food & Drug Administration 850 Third Avenue Brooklyn, NY 11232

WARNING LETTER

October 20, 1999

REF: NYK-2000-05

Facility ID: 127399

CERTIFIED MAIL RETURN RECEIPT REQUESTED

Noah Weg, M.D.

President

Noah Weg & Associates

4 South Airmont Road

Suffern, New York 10901

Dear Dr. Weg:

Your facility was inspected on August 16, 1999 by a representative of the New York State Department of Health, acting in behalf of the Food and Drug Administration (FDA). This inspection revealed serious regulatory problems involving the mammography at your facility.

Under a United States Federal law, the Mammography Quality Standards Act of 1992, your facility must meet specific requirements for mammography. These requirements help protect the health of women by assuring that a facility can perform quality mammography. The inspection revealed the following Level 1 finding at your facility.

1. The medical physicist, and the second of the second of

The specific problem noted above appeared on your MQSA Facility Inspection Report which was issued to your facility at the close of the inspection. This problem is identified as Level 1 because it identifies a failure to meet a significant MQSA requirements.

Because this condition may be symptomatic of serious underlying problems that could compromise the quality of mammography at your facility, it represents a violation of the law which may result in FDA taking regulatory action without further notice to you. These actions include, but are not limited to, placing your facility under a Directed Plan of Correction, charging your facility for the cost of on-site monitoring, assessing civil money penalties up to \$10,000 for each failure to substantially comply with, or each day of failure to substantially comply with, MQSA standards, suspension or revocation of your facility's FDA certificate, or obtaining a court injunction against further mammography.

Noah Weg & Associates Warning Letter NYK-2000-05

In addition, your response should address the Level 2 findings that were listed on the inspection report provided to you at the close of the inspection. The level 2 findings are:

- 1. The interpreting physicians, and the requirement of having initial experience in mammography by having read or interpreted 240 patient examinations in a 6 month period.
- 2. The interpreting physician, failed to meet the continuing experience requirement of having read or interpreted 960 patient examinations in a 24 month period.
- 3. The interpreting physicians, also failed to meet the requirement of having a minimum of 40 CME credit hours of initial training in mammography.
- 4. Five of five random reports reviewed did not contain an assessment category for your site.

It is necessary for you to act on this matter immediately. Please explain to this office in writing within fifteen (15) working days from the date you receive this letter:

- the specific steps you have taken to correct all of the violations noted in this letter;
- each step your facility is taking to prevent the recurrence of similar violations; and
- sample records that demonstrate proper record keeping procedures.

Please submit your response to the attention of Lillian C. Aveta, Compliance Officer, U.S. Food and Drug Administration, 850 Third Avenue, Brooklyn, New York 11232, Tel. (718) 340-7000, ext. 5142.

Finally, you should understand there are many FDA requirements pertaining to mammography. This letter pertains only to findings of our inspection and does not necessarily address other obligations you have under the law. You may obtain general information about all of FDA's requirements for mammography facilities by contacting the Mammography Quality Assurance Program, Food and Drug Administration, P.O. Box 6057, Columbia, Maryland 21045-6057 (1-800-838-7715), or through the Internet at http://www.fda.gov.

Noah Weg & Associates Warning Letter NYK-2000-05

If you have any questions about mammography facility requirements in general, please feel free to contact Murray L. Kurzman, Radiation Programs Manager, at (516) 921-2035.

Sincerely yours,

Brenda J. Holman

District Director